Generation Bio (GBIO) Stock Price, News & Analysis

Company Overview

Generation Bio (NASDAQ: GBIO) is a clinical-stage biotechnology company focused on the development of non-viral, persistent gene therapies aimed at treating rare and prevalent diseases. Utilizing its proprietary GeneVector platform, the company engineers synthetic DNA payloads encapsulated in lipid nanoparticles to achieve safe, durable expression of therapeutic proteins. This platform is designed to overcome limitations of traditional viral vectors by offering controlled gene expression, reduced immunogenicity and scalable manufacturing processes.

The company’s pipeline includes multiple preclinical and early clinical programs targeting genetic disorders of the liver, central nervous system and other organ systems. Generation Bio has announced lead programs in metabolic and hematologic diseases, with plans to expand into indications such as rare enzyme deficiencies and neurological conditions. The company leverages its integrated research, development and manufacturing capabilities to accelerate candidate selection and produce clinical-grade material in-house.

Founded in 2020 and headquartered in Cambridge, Massachusetts, Generation Bio was formed through the merger of 4D Molecular Therapeutics’ non-viral gene therapy platform and Agilis Biotherapeutics’ proprietary vectors. The company maintains key research collaborations and academic partnerships across the United States and Europe, positioning it to advance global clinical development. Its facilities in Greater Boston house specialized teams in vector engineering, analytical development and process scale-up.

Generation Bio’s leadership team is led by Chief Executive Officer John Evans, who brings extensive experience from previous roles at Arvinas and Pfizer. The executive team includes seasoned biopharmaceutical professionals specializing in gene therapy, regulatory affairs and operations. The company’s board of directors comprises industry veterans focused on driving innovation and strategic growth in the emerging field of non-viral gene therapy.

Key Stats

• Today's Range: $0.37 to $0.40
• 50-Day Range: $0.30 to $0.44
• 52-Week Range: $0.30 to $3.65
• Volume: 1.09 million shs
• Average Volume: 408,468 shs
• Market Capitalization: $25.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Buy

Generation Bio Stock Analysis - MarketRank™

Generation Bio scored higher than 77% of companies evaluated by MarketBeat, and ranked 250th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Generation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Generation Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Generation Bio are expected to grow in the coming year, from ($1.75) to ($0.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Generation Bio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Generation Bio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Generation Bio has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.67% of the float of Generation Bio has been sold short.

Short Interest Ratio / Days to Cover

Generation Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Generation Bio has recently decreased by 59.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Generation Bio does not currently pay a dividend.

Dividend Growth

Generation Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.67% of the float of Generation Bio has been sold short.

Short Interest Ratio / Days to Cover

Generation Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Generation Bio has recently decreased by 59.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.87

News Sentiment

Generation Bio has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Generation Bio this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Generation Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GBIO Stock Analysis - Frequently Asked Questions

How have GBIO shares performed this year?

Generation Bio's stock was trading at $1.06 on January 1st, 2025. Since then, GBIO stock has decreased by 63.5% and is now trading at $0.3864.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The company had revenue of $8.72 million for the quarter, compared to the consensus estimate of $1.70 million. Generation Bio had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 292.92%.

When did Generation Bio IPO?

Generation Bio (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Generation Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GBIO
• CIK: 1733294
• Web: generationbio.com
• Phone: 617-655-7500
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Generation Bio: $7.33
• High Price Target: $9.00
• Low Price Target: $5.00
• Potential Upside/Downside: +1,797.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$131.67 million
• Net Margins: -292.92%
• Pretax Margin: -292.92%
• Return on Equity: -75.84%
• Return on Assets: -30.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.43
• Quick Ratio: 8.43

Sales & Book Value

• Annual Sales: $19.89 million
• Price / Sales: 1.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 67,040,000
• Free Float: 52,421,000
• Market Cap: $25.90 million
• Optionable: Optionable
• Beta: 2.59